Searching: http://spark.kufu.no/fhir/_snapshot?id=d995a4cb-bdee-481f-a744-43ab51e00013&start=0
From RowNum: 0
id: d995a4cb-bdee-481f-a744-43ab51e00013 (excluded)
start: 0
First Link: http://spark.kufu.no/fhir/_snapshot?id=d995a4cb-bdee-481f-a744-43ab51e00013&start=0
Last Link: http://spark.kufu.no/fhir/_snapshot?id=d995a4cb-bdee-481f-a744-43ab51e00013&start=0
Type: Searchset, 1 of 1
MedicinalProductInteraction/example/_history/1 Modified: 5/28/2019 2:47:40 PM +02:00

Generated Narrative with Details

id: example

description: Inhibitors of CYP3A4 and P-gp\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\nequixaban Cmax.\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\nsection 4.4).\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.

interactant

item: ketoconazole (Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)

interactant

item: itraconazole (Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)

type: StrongInhibitorofCYP3A4 (Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)

effect: Increasedplasmaconcentrations (Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)

management: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp (Details )